{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:16:35Z","timestamp":1788592595509,"version":"build-2803163510"},"reference-count":61,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The purpose of this study was to describe the safety, tolerability, and efficacy of quetiapine monotherapy continued for up to 26-weeks in youth with schizophrenia or bipolar I disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Medically healthy boys and girls with a baseline\n                      <jats:italic toggle=\"yes\">Diagnostic and Statistical Manual of Mental Disorders, 4th ed.<\/jats:italic>\n                      (DSM-IV-TR) diagnosis of schizophrenia (ages 13\u201317 years) or a manic episode of bipolar I disorder (ages 10\u201317 years) who participated in one of two acute, double-blind, placebo-controlled studies of immediate-release quetiapine were potentially eligible to enroll in a 26-week, open-label study. During the open-label study, quetiapine was flexibly dosed at 400\u2013800\u2009mg\/day, with options to reduce dosing to 200\u2009mg\/day based on tolerability. Safety and tolerability outcomes assessed from open-label baseline to week 26 included adverse events (AEs), metabolic\/laboratory parameters, extrapyramidal symptoms, suicidality, and vital signs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of 381 patients enrolled in the open-label study (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =176, schizophrenia;\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =205, bipolar disorder diagnosis), 237 patients (62.2%) completed the 26-week study period (71.0%, schizophrenia; 54.6%, bipolar disorder). The most common AEs reported during the study included somnolence, headache, sedation, weight increase, and vomiting. A total of 14.9% of patients experienced a shift to potentially clinically significant low levels of high-density lipoprotein cholesterol and 10.2% of patients experienced a shift to potentially clinically significant high triglyceride levels. Weight gain \u22657% was reported in 35.6% of patients between open-label baseline and final visit. After adjustment for normal growth, 18.3% of study participants experienced clinically significant weight gain (i.e., increase in body mass index \u22650.5 standard deviations from baseline).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this 26-week study, quetiapine flexibly dosed at 400\u2013800\u2009mg\/day, with options to reduce dosing based on tolerability, was generally safe and well tolerated in youth. Clinicians should monitor lipid profiles and weight gain in youth with schizophrenia or bipolar disorder during treatment with quetiapine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration information:<\/jats:title>\n                    <jats:p>\n                      Quetiapine Fumarate (Seroquel) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder (ANCHOR 150). Available at:\n                      <jats:uri xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00227305\">http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00227305<\/jats:uri>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2012.0092","type":"journal-article","created":{"date-parts":[[2013,9,11]],"date-time":"2013-09-11T12:29:42Z","timestamp":1378902582000},"page":"490-501","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":27,"title":["Safety, Tolerability, and Efficacy of Quetiapine in Youth with Schizophrenia or Bipolar I Disorder: A 26-Week, Open-Label, Continuation Study"],"prefix":"10.1177","volume":"23","author":[{"given":"Robert L.","family":"Findling","sequence":"first","affiliation":[{"name":"Johns Hopkins Medicine and the Kennedy Krieger Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Pathak","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals LP, Wilmington, Delaware."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willie R.","family":"Earley","sequence":"additional","affiliation":[{"name":"Forest Research Institute, Inc.,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Liu","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals LP, Wilmington, Delaware."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"DelBello","sequence":"additional","affiliation":[{"name":"University of Cincinnati College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2013,9,1]]},"reference":[{"key":"e_1_3_4_2_1","volume-title":"Text Revision","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Text Revision. Washington, DC: American Psychiatric Association, 2000.","edition":"4"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/09638230903469111"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.2.175"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/106342669700500404"},{"key":"e_1_3_4_7_1","unstructured":"Centers for Disease Control and Prevention. Growth charts. 2000. http:\/\/www.cdc.gov\/growthcharts\/. 2013 February 5."},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1549"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0520"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00728.x"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0954579406060597"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2011.0092"},{"key":"e_1_3_4_13_1","first-page":"583","article-title":"Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study","volume":"49","author":"Findling RA","year":"2010","unstructured":"Findling RA, , Johnson JL, , McClellan J, , Frazier JA, , Vitiello B, , Hamer RM, , Lieberman JA, , Ritz L, , McNamara NK, , Lingler J, , Hlastala S, , Pierson L, , Puglia M, , Maloney AE, , Kaufman EM, , Noyes N, , Sikich L. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry, 49:583\u2013594. 2010.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.8125cc10c"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05164yel"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.07061035"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbi014"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2010.07.002"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.10.1130"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2005.00263.x"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.CHI.0000046821.95464.CF"},{"key":"e_1_3_4_22_1","first-page":"534","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy W","year":"1976","unstructured":"Guy W. Abnormal Involuntary Movement Scale. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: U.S. Department of Health, Education, and Welfare, 1976; 534\u2013537."},{"key":"e_1_3_4_23_1","volume-title":"Manual for the ECDEU Assessment Battery","author":"Guy W","year":"1970","unstructured":"Guy W, , Bonato RR. CGI clinical global impression. Manual for the ECDEU Assessment Battery, 2nd. Chevy Chase, MD: U.S. Department of Health, Education and Welfare, 1970; 12\u20131\u201312\u20136.","edition":"2"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00750.x"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2008.0144"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2007.0123"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199707000-00021"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.0b013e3181900404"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.04.043"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a033495"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(94)90104-X"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1984.01790130053007"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2011.0015"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0b013e32833b027e"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0403"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.162.10.929"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2010.00797.x"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02088471"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11m07424"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2010.00850.x"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2004.01.022"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2007.164.7.1035"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0954579401003091"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0954579400007082"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/1753-2000-2-6"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2007.0048"},{"key":"e_1_3_4_49_1","unstructured":"Seroquel\u00ae (quetiapine fumarate) prescribing Information. 2012. http:\/\/www1.astrazeneca-us.com\/pi\/Seroquel.pdf. 2013 February 5."},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.01790100074010"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1089\/104454601317261591"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08050756"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(97)00123-6"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199506000-00012"},{"key":"e_1_3_4_56_1","volume-title":"Growth at Adolescence","author":"Tanner JM","year":"1962","unstructured":"Tanner JM. Growth at Adolescence. Oxford: Blackwell Scientific Publications, 1962."},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.06111932"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903473165"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2007.00498.x"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11m06878"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2009.0037"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2012.0092","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2012.0092","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2012.0092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:55:42Z","timestamp":1777388142000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2012.0092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1089\/cap.2012.0092"],"URL":"https:\/\/doi.org\/10.1089\/cap.2012.0092","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}